How many 8-K filings has Abvc Biopharma, Inc. filed?

Abvc Biopharma, Inc. (ABVC) has 22 8-K (Current Event Report) filings on record, spanning Feb 2024 to Oct 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Abvc Biopharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Abvc Biopharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Abvc Biopharma, Inc. (ABVC) — 8-K Filings

All 8-K filings from Abvc Biopharma, Inc.. Browse 22 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (22)

ABVC Biopharma Announces Board and Executive Changes — Oct 30, 2025 Risk: medium
ABVC Biopharma, Inc. announced on October 28, 2025, changes related to its board of directors and executive compensation. The filing details the departure of ce
ABVC Biopharma Files 8-K on Financials — Aug 14, 2025 Risk: low
On August 14, 2025, ABVC Biopharma, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statemen
ABVC Biopharma Files 8-K for Shareholder Votes & Exhibits — Jun 4, 2025 Risk: low
ABVC Biopharma, Inc. filed an 8-K on June 3, 2025, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. T
ABVC Biopharma Files 8-K on Operations and Financials — May 1, 2025 Risk: low
ABVC Biopharma, Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits.
ABVC Biopharma Shuffles Leadership — Mar 7, 2025 Risk: medium
ABVC Biopharma, Inc. announced on March 5, 2025, a series of executive and board changes. The company elected Dr. Jian-Fu Chen as a new director and appointed D
ABVC Biopharma Files 8-K: Material Agreement & Equity Sales — Jan 6, 2025 Risk: medium
On January 6, 2025, ABVC Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity secu
ABVC Biopharma Files 8-K: Agreements & Equity Sales — Nov 4, 2024 Risk: medium
On November 4, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity sec
ABVC Biopharma Changes Certifying Accountant — Oct 18, 2024 Risk: medium
ABVC Biopharma, Inc. has filed an 8-K report on October 18, 2024, to disclose a change in its certifying accountant. The company has appointed a new independent
ABVC Biopharma Files 8-K Report — Sep 10, 2024 Risk: low
On September 10, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing other events. The company, incorporated in Nevada, is based in Fremont, California, an
ABVC Biopharma Files 8-K: Regulation FD & Exhibits — Aug 20, 2024 Risk: low
On August 20, 2024, ABVC Biopharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spec
ABVC BioPharma Files 8-K on Financials — Aug 15, 2024 Risk: medium
ABVC BioPharma, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
ABVC Biopharma Files 8-K on Director Changes — Jul 23, 2024 Risk: medium
On July 23, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the elec
ABVC Biopharma Faces Delisting Concerns — Jul 12, 2024 Risk: high
ABVC Biopharma, Inc. filed an 8-K on July 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is b
ABVC Biopharma Enters Material Definitive Agreement — May 24, 2024 Risk: medium
ABVC Biopharma, Inc. announced on May 24, 2024, the entry into a material definitive agreement. The company, formerly known as American BriVision (Holding) Corp
ABVC BioPharma Files 8-K: Material Agreement & Equity Sales — May 23, 2024 Risk: medium
On May 23, 2024, ABVC BioPharma, Inc. announced the entry into a material definitive agreement. The company also reported on unregistered sales of equity securi
ABVC Biopharma Files 8-K with Material Agreement Details — May 15, 2024 Risk: medium
On May 15, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits,
ABVC Biopharma Enters Material Definitive Agreement — May 9, 2024 Risk: medium
On May 9, 2024, ABVC Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as American BriVision (Holding) Corp, is incorpor
ABVC Biopharma Files 8-K for Shareholder Votes & Exhibits — Apr 19, 2024 Risk: low
ABVC Biopharma, Inc. filed an 8-K on April 19, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits.
ABVC Biopharma Enters Material Definitive Agreement — Apr 17, 2024 Risk: medium
On April 17, 2024, ABVC Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as American BriVision (Holding) Corp, is incor
ABVC Biopharma Enters Material Definitive Agreement — Mar 26, 2024 Risk: medium
On March 26, 2024, ABVC Biopharma, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this
ABVC Biopharma Files 8-K on Financials — Mar 14, 2024 Risk: medium
ABVC Biopharma, Inc. filed an 8-K on March 14, 2024, reporting on its financial condition and results of operations. The filing details the company's status and
ABVC Biopharma Reports Material Agreement & Unregistered Equity Sale — Feb 8, 2024 Risk: medium
ABVC Biopharma, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securities."

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX